Live corpus
Active intelligence prompt Pediatric cancer: surface high-value therapeutic signals across pediatric oncology literature.
PEDIATRIC CANCER RESEARCH INTELLIGENCE

Finding therapies hidden in 37,224 pediatric cancer papers.

Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.

37,224 Papers indexed
371 Papers AI scored
37,224 Ranked papers
100.0% Coverage
PATIENT-FRIENDLY SUMMARY

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

For education only—not personal medical advice.

LIVE PEDIATRIC ONCOLOGY INTELLIGENCE
↑ Therapeutic signals emerging ↑ New pediatric cancer papers ingested ↑ Cross-paper convergence detected ↑ Human relevance scores updating ↑ Overlooked treatment paths surfacing
TOP PEDIATRIC CANCER SIGNALS

Ranked Discovery Journal Articles

View all discoveries →
PEDIATRIC CANCER RESEARCH TERMINAL

All ranked pediatric cancer papers

37224 results
B
Association of Therapies for Axial Spondyloarthritis on the Risk of Hip and Spine Fractures.
PMID 39679763 Published: 2025-01-21 Ingested: 2026-08-02 12:03 AM Arthritis & rheumatology (Hoboken, N.J.)
AI -
Base 75.6
Rank 75.6
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 75.6/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 38.0; sample size: 100.0; recency: 90.0; abstract quality: 100.0.

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 75.6/100. Study design: 100.0; human relevance: 75.0; therapeutic relevance: 28.0; sample size: 60.0; recency: 90.0; abstract quality: 100.0.

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 75.6/100. Study design: 80.0; human relevance: 95.0; therapeutic relevance: 28.0; sample size: 80.0; recency: 90.0; abstract quality: 100.0.

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 75.6/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 28.0; sample size: 40.0; recency: 90.0; abstract quality: 100.0.

B
AI -
Base 75.59
Rank 75.59
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 75.6/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 73.0; sample size: 20.0; recency: 100.0; abstract quality: 100.0.

B
Comparison of Outcomes With Novel Versus Traditional Chemotherapy Regimens for Relapsed and Refractory Classical Hodgkin Lymphoma.
PMID 41763973 Published: 2026-02-02 Ingested: 2026-08-02 12:06 AM Clinical lymphoma, myeloma & leukemia
AI -
Base 75.58
Rank 75.58
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 75.6/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 87.9; sample size: 60.0; recency: 100.0; abstract quality: 85.0.

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 75.6/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 77.9; sample size: 20.0; recency: 90.0; abstract quality: 100.0.

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 75.5/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 47.7; sample size: 70.0; recency: 100.0; abstract quality: 100.0.

B
Itacitinib in advanced hepatocellular cancer following first line therapy.
PMID 41673081 Published: 2026-02-11 Ingested: 2026-08-02 12:06 AM NPJ precision oncology
AI -
Base 75.54
Rank 75.54
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 75.5/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 95.2; sample size: 30.0; recency: 100.0; abstract quality: 100.0.

Previous
Page 272 of 3102
Next
Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic